Business Context and Reporting Period
This Form 8-K is a current report filed by Magenta Therapeutics, Inc. (not Dianthus Therapeutics, Inc., as indicated in the metadata) on May 2, 2022. The filing discloses the execution of amended and restated employment agreements with two Named Executive Officers (NEOs): Thomas Beetham, Chief Legal Officer, and David Nichols, Chief Technical Officer. The agreements were approved by the Company's Compensation Committee and/or Board of Directors.
Key Financial Metrics and Compensation Terms
The filing does not contain general financial statements, revenue, profit, cash flow, or debt metrics. It focuses exclusively on executive compensation terms effective for fiscal year 2022:
- Thomas Beetham (Chief Legal Officer):
- Base Salary: $435,000
- Target Annual Incentive: 40% of base salary
- David Nichols (Chief Technical Officer):
- Base Salary: $362,000
- Target Annual Incentive: 40% of base salary
Material Changes and Severance Provisions
The primary material change is the update to employment contracts, which supersede prior agreements. Key severance provisions include:
- Standard Termination (Without Cause/Good Reason): Both executives are entitled to 0.75 times their base salary plus a pro-rata portion of their target annual incentive, plus up to nine months of COBRA health insurance premiums.
- Change in Control Termination: If termination occurs within three months before to 12 months after a change in control, benefits increase to:
- 1.0 times base salary plus 100% of the target annual incentive.
- Full accelerated vesting of outstanding time-based stock options and awards.
- Up to 12 months of COBRA health insurance premiums.
Guidance, Risks, and Contingencies
The filing outlines specific tax and legal contingencies related to the Change in Control severance packages:
- Golden Parachute Provisions: Payments may be subject to the excise tax under Section 4999 of the Internal Revenue Code and may not be deductible by the Company under Section 280G. A "gross-up" or reduction mechanism is in place to maximize the executive's net after-tax benefit.
- Health Insurance Compliance: If health insurance payments violate nondiscrimination rules or the Affordable Care Act, they will be treated as taxable lump-sum payments or converted to taxable cash equivalents.
- Covenants: Executives are subject to standard confidentiality, IP assignment, and post-termination non-competition and non-solicitation covenants.
Investor Verification Checklist
- Verify the full text of the employment agreements filed as Exhibit 10.1 (Beetham) and Exhibit 10.2 (Nichols) for complete legal definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the current status of outstanding stock options and awards for both executives to assess the potential cost of accelerated vesting.
- Review the Company's most recent 10-K or 10-Q for actual cash burn and liquidity, as this 8-K does not provide financial position data.
- Monitor for any future filings regarding the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.